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Summary 
Fragmented human erythrocyte  membranes were exposed to PbC12 for 10-- 
40 min at 23°C prior to (Na÷+ K+)-ATPase assay. Inhibition increased with 
exposure time. Enzyme activity in 5 pg membrane protein was inhibited 50% 
after a 10-min exposure to 1.0 nmol PbC12 (25 pM final concentration) and 
was inhibited 100% after 40 rain. When membranes at various concentrations 
were exposed to PbC12 for 40 min, inhibition was linear with the ratio of PbC12 
to protein. Inhibition of 100% was obtained at 0.2 nmol PbC12/pg protein. A 
graph of activity vs. [protein] in the presence of PbC12 intercepted the abscissa 
to the right of  the origin, indicating that  lead acts as an irreversible or very 
slowly reversible inhibitor. Addition of 1 mM 2,3-dimercaptopropanol, 1,3- 
dithiothreitol,  DL-penicillamine or EDTA after 40 min exposure to 100 pM 
PbC12 restored 45, 64, 81 and 92% of the (Na ÷ + K+)-ATPase, respectively. 
These chelators, excluding EDTA, prevented inhibition when added before 
PbC12. Two washings of the membrane fragments with water or 10 mM imid- 
azole-HC1 (pH 7.4) did not restore activity. 21°Pb bound tightly to membrane 
fragments and beginning of saturation was observed at 0.19 nmol Pb 2÷ bound/  
pg protein. This corresponded to 200 pM final concentration of PbC12 in the 
ATPase assay. At 0.2 nmol PbC12/pg protein {100% inhibition of ATPase), 
from 0.10--0.17 nmol of  lead was bound per pg protein. Under the same 
conditions, 1 mM DL-penicillamine removed 80% of the bound lead which 
correlated with its restoration of ATPase activity. Pb 2÷ does not  appear to 
* This work was presented to t h e  F e d e r a t i o n  of American S o c i e t i e s  f or  Experimental  Biology, April 1-- 
10, 1979, Dallas, TX, U.S.A. (Fed. Proc. (1979) 38 ,321 . )  
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denature the enzyme. The irreversible kinetics may be related to sequestration 
of Pb 2÷ within vesicles that  interfere with the accessibility of chelators to 
Pb 2÷ binding sites. 
Introduction 
Among the clinical symptoms of inorganic lead poisoning is anemia. Possible 
molecular mechanisms which have been suggested include defects in heme 
synthesis [1,2] and direct effects of lead on the erythrocyte  membrane. Lead 
binding to red cells in vitro results in altered fragility [3] and ion transport 
[4,5]. Also, lead has been shown to induce conformational  changes in the 
membrane proteins [6]. Deficiencies in the erythrocyte  membrane (Na ÷ + K+) - 
ATPase have been reported in factory workers exposed to lead [7] and in 
urban children [8]. 
Inorganic lead has been found to inhibit the microsomal (Na ÷ + K+)-ATPase 
of rat brain, rat kidney [9] and Electrophorus electroplax [10]. In electroplax, 
the enzyme is inhibited non-competitively and reversibly but the extent  of 
inhibition depends on the ratio of PbC12 to protein. The activity can be 
restored readily by dilution of the microsomes or by the addition of metal 
ion chelators. Similar results were found using preparations from human 
kidney and various organs of the dog [11]. 
In the present study, lead inhibition of human erythrocyte  membrane 
(Na ÷ + K+)-ATPase is found to be irreversible or very slowly reversible in the 
absence of chelators. The inhibition can be correlated with binding of 21°pb 
to the membranes. 
Materials and Methods 
Packed human red blood cells Were obtained from the University of Michi- 
gan Blood Bank and the Southeastern Michigan Blood Center of the Red 
Cross. The Tris salt of ATP, DL-penicillamine, EDTA, 2,3-dimercaptopropanol 
and 1,3-dithiothreitol were obtained from Sigma Chemical Co. ICN and Amers- 
ham were the sources of [7-32P]ATP and 21°PbNO3, respectively. Enzyme 
incubations were performed in disposable borosilicate glass tubes (Kimble, 
No. 7300, 6 × 50 mm). 
Red cell membranes were prepared according to the method of Post et al. 
[12] with certain modifications. Whole blood, 5 ml, was suspended in 0.5 ml 
of 0.2 M Na4EDTA and 30 ml of 0.15 M NaC1. The cells were packed by 
centrifugation at 9750 × g for 30 min and were washed three more times in 
saline. Cell lysis was performed with 5 mM Tris-HC1 (pH 7.4) and the frag- 
ments were sedimented at 9750 X g and washed twice more in this buffer. 
At this stage the pellets were pink. Further purification was obtained by 
resuspension in 4-ml of 0.1 M Tris-glycylglycine (pH 8.0) plus 25-ml water. 
If necessary, another wash in 0.5 mM Tris-glycylglycine (pH 8.0) was per- 
formed. All procedures were carried out at 0--2°C. The membranes were 
stored in a concentration of 8--12 mg protein/ml in 5 mM Tris-HC1 (pH 7.4) 
at 4°C and were used within 2 weeks. Protein concentration measurements 
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were made according to the method of Lowry et al. [13]. The yield from this 
procedure averaged 16 mg membrane protein per 5 ml whole blood. 
Hydrolysis of [7-32P]ATP was measured as described by Siegel and Albers 
[14]. The final reaction mixture contained 2 mM MgC12, 2 mM Tris-ATP, 
10 mM imidazole-HC1 (pH 7.4), 80 mM NaC1, 20 mM KC1, and membrane 
fragments containing 5--20 pg protein in a total volume of 40 pl. Mg2÷-ATPase 
activity was measured under all conditions, tested in the absence of NaC1 and 
KC1 and subtracted from the total to give (Na ÷ + K÷)-increments. The enzyme 
was exposed to PbC12 for periods of 10--40 min at 23°C prior to assay. The 
activity of  the control samples not  exposed to lead was unaffected over these 
time periods. ATP hydrolysis was initiated by the addition of the reaction 
mixture. Incubations were carried out for 45 min at 37 ° C. The data represent 
the mean of duplicate samples that  differ by less than 5%. 
Dilution experiments were performed as follows. Membranes were exposed 
to PbCl: at a ratio of 0.2 nmol PbC12/pg protein in a final volume of 375 pl 
at 23°C for 40 min. Five aliquots of 15 pl were removed for protein deter- 
mination and ATPase assays. The remaining suspension was diluted by the 
addition of 3-ml H~O or 10 mM imidazole-HC1 (pH 7.4) and after 5 min at 
23°C, was centrifuged at 12100 × g  for 30 min. The supernatant portion 
was aspirated and the pellet was resuspended in 300-pl H20 or buffer. Ali- 
quots were removed and the procedure was repeated. 
In the lead-binding experiments, erythrocyte  membranes (0.5 mg protein) 
were exposed to 10--400 nmol PbC12 plus 30 pmol 21°pb in a final volume 
of 375 pl (0.02--0.8 nmol PbC12/pg protein). Aliquots were removed for 
scintillation counting (40-pl) and protein determination (15-pl). Following 
a 40 min exposure at 23°C the membranes were washed twice with imidazole- 
HC1 exactly as in the dilution experiments for reversal of inhibition described 
above. The final pellets were resuspended in 225-pl of imidazole-HC1 and 
aliquots were removed for measurements of protein and bound 21°pb. 21°Pb 
determination was performed with the use of a Packard Model 3375 liquid 
scintillation spectrometer. The fluid consisted of 8 g 2,5-diphenyloxazole, 
0.2 g 1,4-bis(2-(5-phenyloxazolyl))benzene, 1 1 of Cellosolve * (purified). 
Parallel samples of  incubation mixtures without  membranes and subjected to 
the same washing procedures showed no significant retention of radioactiv- 
ity by the glassware. In some of the lead experiments, DL-penicillamine was 
added after the 40 min exposure of protein to 21°Pb. After a second 40 min 
incubation at 23°C, the washing procedures were performed as described 
above. 
Results and Discussion 
E f f e c t s  o f  Pb 2÷ on (Na ÷ + K*)-ATPase  
Inhibition by PbC12 increases as a function of  exposure time. When 5 pg 
membrane protein are first treated with 1 nmol PbC12 (25 pM), the (Na ÷ + K+) - 
ATPase activity is inhibited 50% at 10 min and 100% at 40 min of exposure 
(Fig. 1). The exposure time necessary to produce 100% inhibition varies with 
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Fig. 3. Rate  o f  ( N a + +  K+)-dependent  ATPase  hydro lys i s  as a f u n c t i o n  o f  m e m b r a n e  prote in  c o n c e n -  
trat ion .  Prior to  assay the  m e m b r a n e  f r agm e n t s  w e r e  e x p o s e d  for  4 0  m i n  at 23~C to  H 2 0  ( e  . . . . . .  e ) ,  or  
1 n m o l  PbCl 2 (x  x )  i n  1 5  p l .  Th e  final c o n c e n t r a t i o n  o f  PbC12 is 2 5  ~ M  i n  a final v o l u m e  o f  4 0  pl 
a f ter  add i t i on  o f  reac t ion  m i x t u r e .  
protein concentration. At PbC12 concentration of  100 pM, enzyme activity 
in 5 pg protein is totally inhibited after an exposure time of 10 min {Fig. 1), 
but when 20 pg protein are employed 40 min of  exposure are required for 
complete inhibition (Fig. 2). After 40 min exposure, the [PbC12]0.s is 8 and 
28.5 pM for 5 and 20 pg protein, respectively (Fig. 2). The Mg2÷-ATPase 
activity is also inhibited by PbC12 and values for each data point have been 
subtracted to give the (Na ÷ + K÷)-ATPase increments. The Mg 2÷ and (Na ÷ + K÷) - 
ATPase activities of  controls which were exposed to water rather than PbC12 
were unaffected during these exposure conditions. 
Inhibition of  the (Na ÷ + K+)-ATPase is linear with the PbC12 : protein ratio 
in the range from 0.05 to 0.2 nmol PbC12/pg protein (data not shown). The 
value for [PbC12]0.5 corresponds to 0.085 nmol PbC12/pg protein at a time 
of  exposure close to equilibrium. This is in agreement with values for half- 
maximal inhibition calculated from Fig. 2 : 0 . 0 7  and 0.06 nmol PbC12/pg 
protein obtained with either 5 or 20 pg protein, respectively. Accurate data 
are difficult to obtain at low PbC12 :protein ratios presumably because the 
excess amount of  protein increases the number of non-enzyme binding sites 
and decreases free Pb 2÷ and also because of  the difficulty in obtaining equi- 
librium at low concentrations. 
After a 40 min exposure to 1 nmol PbC12 (25 pM), the rate of  ATP hydro- 
lysis i s  completely inhibited with 5 pg protein (Fig. 3). The fact that the 
curve intercepts the abscissa to the right of  the origin suggests that the lead- 
induced inhibition is irreversible or very slowly reversible [ 15 ]. 
Washing experiments were performed in an attempt to dissociate the Pb 2÷ 
by dilution {Table I). Enzyme activity could not be restored by dilution 
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T A B L E  I 
R E S I D U A L  Pb 2+ I N H I B I T I O N  O F  E R Y T H R O C Y T E  (Na + + K+)-ATPase  A F T E R  W A S H E S  
M e m b r a n e  f r a g m e n t s  c o n t a i n i n g  0 .5  m g  p r o t e i n  were  e x p o s e d  to 100  n m o l  PbCI 2 in a v o l u m e  of  375  pl 
for  40  m i n  at  23°C .  W ash ing  p r o c e d u r e s  are  d e s c r i b e d  in Mater ia ls  a n d  Me thods .  Values  axe p e r c e n t  inhib i -  
t i o n  o f  (Na + + K+)-ATPase  ac t i v i t y  re la t ive  to  con t ro l  s a m p l e s  e x p o s e d  u n d e r  the  s a m e  c o n d i t i o n s  b u t  
w i t h o u t  l ead  a n d  r e p r e s e n t  the  m e a n  of  dup l i ca t e  e x p e r i m e n t s  t h a t  d i f f e r  by  less t h a n  10%. 
T r e a t m e n t  % i n h i b i t i o n  
H 2 0  w a s h e s  I m i d a z o l e - H C l  w a s h e s  
In i t ia l  88 60  
Wash 1 88 100  
Wash 2 100  - -  
either with water or imidazole-HC1 buffer (pH 7.4). The dilution factors in 
this experiment were 200-fold for wash 1 and 40 000-fold for wash 2, assum- 
ing that  the pellet volume was 15 pl after each centrifugation. A third wash 
also failed to reverse the Pb 2÷ inhibition; however 86% of the enzyme activ- 
ity in the control samples was lost at this step. 
Chelators, on the other hand, are able to partially reverse the inhibition 
of the ATPase by PbC12 when they are added after enzyme exposure to PbC12 
(Table IIA). The chelators were added to the inhibited enzyme in 10-fold 
molar excess over the PbC12 for 40 min prior to the ATPase assay. The order 
of effectiveness in restoring activity after PbCI2 inhibition is EDTA > DL- 
penicillamine > 1,3-dithiothreitol > 2,3-dimercaptopropanol. The reaction 
mixture for the enzyme incubated with EDTA contained 4 mM MgCl: instead 
of the 2 mM used in other assays because at 2 mM MgC12, EDTA reduces 
the activity of the controls by chelation of the Mg 2÷ needed for enzyme acti- 
vation. In contrast to their partial restorative effects when added after inhi- 
bition has developed, penicillamine, dithiothreitol,  and 2,3-dimercaptopro- 
panol are able to completely prevent PbC12 inhibition of the (Na ÷ + K*)-ATPase 
T A B L E  II  
R E V E R S A L  O F  Pb 2+ I N H I B I T I O N  BY C H E L A T O R S  
(A)  M e m b r a n e  f r a g m e n t s  c o n t a i n i n g  20 lzg p r o t e i n  were  e x p o s e d  to 4 .0  n m o l  PbC12 in a v o l u m e  of  15 pl 
for  40  ra in  at  23°C .  T h e n ,  a f t e r  a d d i n g  40  n m o l  c h e l a t o r  or an  e q u i v a l e n t  v o l u m e  of  wa te r ,  m e m b r a n e s  
r e m a i n e d  a t  230C for  a s e c o n d  40  m i n  e x p o s u r e .  Values  axe p e r c e n t  i n h i b i t i o n  re la t ive  to  c o n t r o l  s a mp le s  
t r e a t e d  w i t h  che l a to r  b u t  no  PbC12. In  b o t h  A a n d  B, t he  r e a c t i o n  m i x t u r e  for  t he  s a m p l e s  r ece iv ing  
E D T A  c o n t a i n e d  4 m M  MgC12. O t h e r w i s e ,  a s says  w e r e  p e r f o r m e d  as d e s c r i b e d  in Mate r ia l s  a n d  Me thods .  
(B) T h e  w a t e r  or c h e l a t o r  was  a d d e d  to the  m e m b r a n e  f r a g m e n t s  40  r a in  p r io r  to  a d d i t i o n  o f  PbC12. 
Va lues  axe p e r c e n t  i n h i b i t i o n  re la t ive  to  c o n t r o l  samples  treated in  a s imilax fasl~_ion b u t  w i t h o u t  PbCI  2 . 
Che l a to r  % I n h i b i t i o n  
A B 
N o n e  100  100  
2 , 3 - D i m e r c a p t o  p r o p a n o l  55 0 
1,3-Dith iothre i to l  36 0 
D L - P e n i c i l l a m i n e  19 0 
E D T A  8 20 
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when they are added to enzyme prior to PbCl~ (Table II). The reduced ability 
of these chelators to restore activity might be due either to reduced acces- 
sibility to membrane-bound lead or to irreversible effects produced by lead. 
The reason for the 20% inhibition in the presence of EDTA in this experiment 
is not  known. 
Pb z÷ binding to membrane fragments 
We wished to see if the inhibitory effects of PbC12 on the (Na ÷ + K÷)-ATPase 
could be correlated with Pb 2÷ binding to membrane fragments. We chose 
conditions of incubation time (40 min) and lead: protein ratios which corre- 
spond to conditions in Fig. 2. It was found that  21°Pb binds tightly to the 
membrane fragments and withstands at least two washings. Under the enzyme 
assay conditions, total  inhibition of the (Na÷+ K÷)-ATPase occurs at 0.2 
nmol PbClz/#g protein. At this ratio, saturation of all binding sites has not  
occurred (Fig. 4) suggesting that  Pb 2÷ is binding to non-enzyme sites on the 
membrane. At higher concentrations of PbC12, measurements of 21°pb binding 
are impossible because of obvious clumping of  the membranes. 
DL-Penicillamine is able to remove 80% of bound Pb 2÷ when added in 
10-fold excess 40 min after PbC12 exposure (0.2 nmol PbC12//~g protein, data 
not  shown). This observation is correlated with the ability of DL-penicillamine 
to restore 80% of the (Na ÷ + K÷)-ATPase activity under the same conditions 
(Table IIA). This indicates that  the Pb 2÷ does not  irreversibly denature the 
enzyme and that  enzyme inhibition depends on continued binding of  Pb 2÷ 
to critical sites. 
It is possible that  lead may be sequestered inside small vesicles formed by 
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membrane fragments. This may account for the slow development of inhibi- 
tion and failure of 40 000-fold dilution of the lead to reverse the inhibition 
of the (Na++ K*)-ATPase. The ability of chelators to partially reverse the 
inhibition may be related to the large stability constants of lead-chelator 
complexes (e.g., approx. 1.101~ for Pb2÷-EDTA complexes [16]). Vesicle 
formation may also account for the reduced ability of chelators in restoring 
activity in contrast to preventing inhibition. If, indeed, vesicles do form, 
some may be inside-out while others are right-side-out [17]. Lead is thought  
to act near the Na ÷ site on phosphorylatable enzyme units oriented toward 
the cytoplasmic side of the membrane [18]. The degree of reversibility would 
be proportional to the percentage of inside-out vesicles (where chelators would 
have easy access to inhibitory lead) and to the permeability of the membranes 
to the chelators. Further experiments are necessary to examine these pos- 
sibilities. 
It is of interest to examine the constraints in seeking a possible relationship 
between these in vitro results and human lead intoxication, since alteration 
of cation transport could result in increased red cell fragility. The present 
data show that  the extent  of  inhibition of (Na ÷ + K+)-ATPase can be related 
to the ratio of lead to membrane protein. Significant inhibition (10%) is 
observed at a ratio of 20 pmol Pb2÷: pg protein (Fig. 2). In patients with 
clear clinical evidence of lead intoxication, the whole blood levels of lead 
range from 100 to 1000 pg/100 g whole blood or higher [19], more than 
90% of which is sequestered with the red cells [8,20]. If one assumes 320 mg 
membrane protein per 100 g whole blood (yield data in Materials and Methods) 
and that  all of the lead is accessible to the (Na ÷ + K+)-ATPase (which, of course, 
may not  be so since much of the lead may be bound m proteins such as hemo- 
globin [21]), then in clinical lead intoxication at most  1.5--15 pmol Pb2+: pg 
membrane protein would be available for inhibiton. Although it is difficult to 
compare in vitro conditions with those found in vivo, in cases of extreme 
toxici ty there may be a significant inhibition of the (Na++ K+)-ATPase, 
whereas at the lower limit of  toxicity no clear evidence for inhibition exists 
based on these data. We have shown, however, that  lead inhibition of the 
(Na++ K*)-ATPase develops slowly. It is possible that  chronic exposure to 
lower levels of lead in vivo might result in a higher degree of inhibition than 
that  which is observed after the 40 min in vitro incubation. Instability of the 
enzyme complicates such studies in vitro. Indeed, Angle and McIntire [8] 
report that  the erythrocyte  (Na ÷ + K+)-ATPase of urban children is decreased 
when red cell lead levels exceed 40 pg/100 ml (greater than 0.7 pmol Pb2+: 
pg membrane protein). These findings are supported by Hasan et al. [7]. 
In both reports the decrease was slight and without  a linear correlation 
between the low blood lead levels and enzyme activity. Further studies are 
necessary to assess the relationship between higher blood levels and degree 
of inhibition of the (Na ÷ + K+)-ATPase. 
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